Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Xing-Mei Cao"'
Autor:
Bai-Yan Wang, Wan-Hong Zhao, Yin-Xia Chen, Xing-Mei Cao, Yun Yang, Yi-Lin Zhang, Fang-Xia Wang, Peng-Yu Zhang, Bo Lei, Liu-Fang Gu, Jian-Li Wang, Ju Bai, Yan Xu, Xu-Geng Wang, Rui-Li Zhang, Li-Li Wei, Qiu-Chuan Zhuang, Frank Fan, Wang-Gang Zhang, Ai-Li He, Jie Liu
Publikováno v:
Journal of Medical Case Reports, Vol 16, Iss 1, Pp 1-8 (2022)
Abstract Background Multiple myeloma remains incurable despite treatment advancements over the last 20 years. LCAR-B38M Cells in Treating Relapsed/Refractory Multiple Myeloma was a phase 1, first-in-human, investigator-initiated study in relapsed/ref
Externí odkaz:
https://doaj.org/article/c9b293fef2f645698bfc3549329d7fc0
Autor:
Wan-Hong Zhao, Bai-Yan Wang, Li-Juan Chen, Wei-Jun Fu, Jie Xu, Jie Liu, Shi-Wei Jin, Yin-Xia Chen, Xing-Mei Cao, Yun Yang, Yi-Lin Zhang, Fang-Xia Wang, Peng-Yu Zhang, Bo Lei, Liu-Fang Gu, Jian-Li Wang, Hui Zhang, Ju Bai, Yan Xu, Han Zhu, Juan Du, Hua Jiang, Xiao-Hu Fan, Jian-Yong Li, Jian Hou, Zhu Chen, Wang-Gang Zhang, Jian-Qing Mi, Sai-Juan Chen, Ai-Li He
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-12 (2022)
Abstract Background LCAR-B38M is a chimeric antigen receptor T cell product with two binding domains targeting B cell maturation antigen. Our previous reports showed a remarkable efficacy of LCAR-B38M in patients with relapsed/refractory multiple mye
Externí odkaz:
https://doaj.org/article/680bd4fe1f994d6db669554110364f34
Autor:
Wan-Hong Zhao, Jie Liu, Bai-Yan Wang, Yin-Xia Chen, Xing-Mei Cao, Yun Yang, Yi-Lin Zhang, Fang-Xia Wang, Peng-Yu Zhang, Bo Lei, Liu-Fang Gu, Jian-Li Wang, Nan Yang, Ru Zhang, Hui Zhang, Ying Shen, Ju Bai, Yan Xu, Xu-Geng Wang, Rui-Li Zhang, Li-Li Wei, Zong-Fang Li, Zhen-Zhen Li, Yan Geng, Qian He, Qiu-Chuan Zhuang, Xiao-Hu Fan, Ai-Li He, Wang-Gang Zhang
Publikováno v:
Journal of Hematology & Oncology, Vol 11, Iss 1, Pp 1-8 (2018)
Abstract Background Chimeric antigen receptor (CAR) T cell therapy has demonstrated proven efficacy in some hematologic cancers. We evaluated the safety and efficacy of LCAR-B38M, a dual epitope-binding CAR T cell therapy directed against 2 distinct
Externí odkaz:
https://doaj.org/article/465fd456636849ce93bd874e19984b0a
Autor:
Bai-Yan Wang, Wan-Hong Zhao, Yin-Xia Chen, Xing-Mei Cao, Yun Yang, Yi-Lin Zhang, Fang-Xia Wang, Peng-Yu Zhang, Bo Lei, Liu-Fang Gu, Jian-Li Wang, Ju Bai, Yan Xu, Xu-Geng Wang, Rui-Li Zhang, Li-Li Wei, Qiu-Chuan Zhuang, Frank Fan, Wang-Gang Zhang, Ai-Li He, Jie Liu
Publikováno v:
Journal of medical case reports. 16(1)
Background Multiple myeloma remains incurable despite treatment advancements over the last 20 years. LCAR-B38M Cells in Treating Relapsed/Refractory Multiple Myeloma was a phase 1, first-in-human, investigator-initiated study in relapsed/refractory m
Autor:
Wanggang Zhang, Rui-Li Zhang, Liufang Gu, Hongli Chen, Xing-Mei Cao, Bo Lei, Yi-Lin Zhang, Li-Li Wei, Ju Bai, Wan-Hong Zhao, Aili He, Yun Yang, Yin-Xia Chen, Jie Liu, Xiao-Hu Fan, Qiu-Chuan Zhuang, Fang-Xia Wang, Pengyu Zhang, Baiyan Wang
Publikováno v:
Frontiers of Medicine. 13:610-617
Chimeric antigen receptor T (CAR-T) cell therapy is a novel cellular immunotherapy that is widely used to treat hematological malignancies, including acute leukemia, lymphoma, and multiple myeloma. Despite its remarkable clinical effects, this therap
Autor:
Zongfang Li, Wanggang Zhang, Rui-Li Zhang, Yan Geng, Qiu-Chuan Zhuang, Yun Yang, Baiyan Wang, Hui Zhang, Yin-Xia Chen, Jie Liu, Zhenzhen Li, Qian He, Ju Bai, Li-Li Wei, Pengyu Zhang, Jianli Wang, Liufang Gu, Xing-Mei Cao, Nan Yang, Yi-Lin Zhang, Xiao-Hu Fan, Ying Shen, Xu-Geng Wang, Yan Xu, Bo Lei, Fang-Xia Wang, Ru Zhang, Wan-Hong Zhao, Aili He
Publikováno v:
Journal of Hematology & Oncology, Vol 11, Iss 1, Pp 1-8 (2018)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Background Chimeric antigen receptor (CAR) T cell therapy has demonstrated proven efficacy in some hematologic cancers. We evaluated the safety and efficacy of LCAR-B38M, a dual epitope-binding CAR T cell therapy directed against 2 distinct B cell ma
Autor:
Ying Shen, Hongli Chen, Wanggang Zhang, Yun Yang, Yin-Xia Chen, Fang-Xia Wang, Jianli Wang, Xing-Mei Cao, Ju Bai, Aili He, Xiao-Rong Ma, Wan-Hong Zhao, Yuandong Feng, Jie Liu
Publikováno v:
Medicina Clínica (English Edition). 151:339-344
Introduction and objective To improve the complete remission (CR) rate of newly diagnosed acute myeloid leukemia (AML) patients and alleviate the severe side effects of double induction chemotherapy, we combined a standard regimen with granulocyte co
Autor:
Walayat Shah, Xiao-Rong Ma, Meili Gao, Fengmei Cai, Wanggang Zhang, Pengyu Zhang, Wan-Hong Zhao, Jianli Wang, Aili He, Jie Liu, Yun Yang, Yin-Xia Chen, Jing Luo, Xing-Mei Cao, Yan-Ping Zhang, Yang Zhang, Xin Meng, Baiyan Wang, Lu Qian, Yan Xu, Bo Lei
Publikováno v:
Journal of Cancer
MLAA-34 is a novel leukemia-associated gene closely related to the carcinogenesis of acute monocytic leukemia (AML). MLAA-34 over expression has been observed to inhibit apoptosis in vitro. JAK2/STAT3 pathway plays an important role in cell prolifera
Autor:
Bo, Lei, Wang-Gang, Zhang, Ai-Li, He, Yin-Xia, Chen, Xing-Mei, Cao, Wan-Hong, Zhao, Jian-Li, Wang, Jie, Liu, Xiao-Rong, Ma, Peng-Yu, Zhang, Ju, Bai
Publikováno v:
Zhongguo shi yan xue ye xue za zhi. 27(3)
To clone the promoter sequence of acute monocytic leukemia new antigen gene.MLAA-34 and identify its promoter core region.The full-length fragment of MLAA-34 gene promoter region was amplified by PCR, then was ligated into pGL3-Basic vector, and the
Autor:
Jianli Wang, Wanggang Zhang, Frank Xiao-Hu Fan, Xing-Mei Cao, Baiyan Wang, Yun Yang, Yin-Xia Chen, Wan-Hong Zhao, Aili He, Liufang Gu, Bo Lei, Jie Liu, Yi-Lin Zhang, Pengyu Zhang, Fang-Xia Wang
Publikováno v:
Blood. 136:6-6
Background: Extramedullary disease (EMD) is characterized as the presence of myeloma cells invasion outside the bone marrow in a patient with multiple myeloma (MM), it may be found 6%~8% in de novo patients, and 10% to 30% in relapsed or refractory (